Low-dose rapamycin alleviates clinical symptoms of fatigue and PEM in ME/CFS patients via improvement of autophagy: a pilot study.
Ruan, Brian T, Bulbule, Sarojini, Gile, Brooke et al. · Journal of translational medicine · 2025 · DOI
Quick Summary
Researchers tested a low-dose drug called rapamycin in 86 ME/CFS patients to see if it could reduce fatigue and post-exertional malaise (PEM). About 74% of patients who completed the first month showed improvements in fatigue, PEM, and other symptoms, and the drug appeared safe with no serious side effects. The study suggests that rapamycin may work by fixing a cellular process called autophagy, which appears to be broken in ME/CFS patients.
Why It Matters
This study provides evidence that a targetable biological mechanism—mTOR-mediated autophagy disruption—may drive ME/CFS symptoms, opening a potential therapeutic pathway. The safety profile and symptom improvements suggest rapamycin warrants further investigation in controlled trials, potentially offering the first disease-modifying treatment for ME/CFS.
Observed Findings
74.3% of completers (52/70) showed recovery in fatigue, PEM, and orthostatic intolerance by day 30, with sustained improvements through day 90
Plasma pSer258-ATG13 levels were significantly downregulated at day 30 (T1)
Plasma BECLIN-1 levels were elevated at day 90 (T3)
Rapamycin at 6 mg/week was tolerated with no serious adverse events reported
Spearman correlation analysis showed association between autophagy impairment markers and reduced activity levels
Inferred Conclusions
Low-dose rapamycin improves core ME/CFS symptoms (fatigue, PEM, OI) via enhancement of autophagy pathways
mTOR inhibition may be a viable therapeutic strategy for autophagy-disruption subtypes of ME/CFS
Autophagy biomarkers (pSer258-ATG13, BECLIN-1) correlate with clinical symptom improvement and may reflect mechanistic action
Future work should identify patient subgroups with mTOR-mediated autophagy dysfunction to enable precision treatment
Remaining Questions
What is the optimal rapamycin dose, and how does it balance efficacy against long-term safety concerns?
What This Study Does Not Prove
This study does not prove rapamycin is effective, as it lacks a control group and placebo comparison; observed improvements could reflect natural variation, placebo effect, or regression to the mean. It does not establish that autophagy dysfunction is the primary cause of ME/CFS, only that it may be associated with symptoms in some patients. The study cannot identify which patients will respond, as no baseline predictive markers were validated.